<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02746718</url>
  </required_header>
  <id_info>
    <org_study_id>14-PP-13</org_study_id>
    <nct_id>NCT02746718</nct_id>
  </id_info>
  <brief_title>Frequency of Pompe's Disease and Neuromuscular Etiologies in Patients With Restrictive Respiratory Failure Associated With Signs of Muscle Weakness</brief_title>
  <acronym>POPS3</acronym>
  <official_title>Frequency of Pompe's Disease and Neuromuscular Etiologies in Patients With Restrictive Respiratory Failure Associated With Signs of Muscle Weakness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A breach of respiratory function may be one of the elements more or less early or predominant
      clinical picture of neuromuscular diseases. It is considered that the obstructive syndromes
      represent 64% and restrictive or mixed syndromes 36% of chronic respiratory insufficiency,
      approximately 7% due to a neuromuscular disease. The frequency and type of impairment are
      dependent on the underlying pathology.

      The neuromuscular restrictive respiratory failure (IRR) remains partially unknown
      pulmonologists, especially because the signs of muscle weakness are sometimes difficult to
      detect. However, respiratory diseases are a major concern in neuromuscular diseases because
      they can have an impact both on sleep (not sleep, ...) on the daily activities
      (breathlessness on exertion, dyspnea) and thereby alter the quality of life of patients.
      Moreover, they represent a significant morbidity and mortality factor. Chest tightness may in
      some cases reveal the disease and thus constitute the chief complaint of a patient with a
      neuromuscular disease. In late-onset Pompe disease, lung disease is the predominant clinical
      symptoms in about 30% of patients.

      An algorithm was developed to guide practitioners and help them in their diagnostic approach
      to the cause of the IRR (diagnostic algorithm ATS / ERS 2005). However, this algorithm does
      not allow precise identification of the neuromuscular causes.

      At the patient level, this can have an impact by extending the time before placing a
      diagnosis. In Pompe disease, the average time to diagnosis reached 7.9 years. However, there
      are for this disease a simple and rapid diagnostic test. Therefore, a greater awareness of
      practitioners with regard to the particular Pompe disease and neuromuscular diseases in
      general may be beneficial to patients.

      This study aims to:

      i) awareness pulmonologists to the possibility of neuromuscular an IRR.

      ii) characterize the frequency of neuromuscular origin of IRR in a broad population of
      patients with concomitant signs muscle weakness.

      iii) reduce the time to diagnosis by directing patients to neuromuscular reference center
      early.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 11, 2015</start_date>
  <completion_date type="Anticipated">December 11, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 11, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of new cases of Pompe disease diagnosed by a positive DBS</measure>
    <time_frame>At the inclusion</time_frame>
    <description>Number of new cases of Pompe disease diagnosed by a positive DBS in patients with unexplained restriction pulmonaires.ries volumes, the patient is adressed to a specialist to dertermine etilogy of the muscular disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of new cases and etiologies of neuromuscular diseases diagnosed in patients with unexplained restriction of lung volumes</measure>
    <time_frame>at 6 month</time_frame>
    <description>If a patient have an high CPK rate or a blotter test positive for Pompe disease or a suspicion of muscular disease with the muscular questionnaires, the patient is addressed to a specialist to determine etiology of the muscular disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and description of neurological symptoms associated with neuromuscular diseases to respiratory revelation</measure>
    <time_frame>at 6 month</time_frame>
    <description>If a patient have an high CPK rate or a suspicion of muscular disease with the muscular questionnaires, the patient is addressed to a specialist to determine etiology of the muscular disease.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Pompe Disease</condition>
  <arm_group>
    <arm_group_label>Restrictive Respiratory Failure</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A CPK dosage, muscular questionnaires and a Pompe Disease test are practiced on patient with Restrictive Respiratory Failure without etiology</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>A blood sample for CPK dosage and pompe disease test</description>
    <arm_group_label>Restrictive Respiratory Failure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of a CV &lt;80% of predicted and / or &lt;LIN

          -  Presence spirometry a report Tiffeneau (FEV / CV) equal to or higher than normal

          -  Signature of informed consent

          -  Men and women age ≥ 18 years

          -  Production of a medical examination

          -  Affiliated to social security

        Exclusion Criteria:

          -  restrictive breath traumatic

          -  restrictive respiratory failure associated with parenchymal disorder, whether
             localized or diffuse

          -  known neuromuscular disease associated with a restrictive lung disease

          -  Patient under guardianship, curatorship, protected by law

          -  Inability to cooperate

          -  Morbid obesity with a BMI ≥40
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabrina Sacconi</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nice</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabrina Sacconi</last_name>
    <phone>0492035505</phone>
    <email>sacconi.s@chu-nice.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hélène PRIGENT</last_name>
    <email>helene.prigent@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trzepizur</last_name>
      <email>WoTrzepizur@chu-angers.fr</email>
    </contact>
    <investigator>
      <last_name>Trzepizur</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier d'Argenteuil</name>
      <address>
        <city>Argenteuil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laure Belmont</last_name>
      <email>Laure.belmont@ch-argenteuil.fr</email>
    </contact>
    <investigator>
      <last_name>Laure Belmont</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice Rannou, PH</last_name>
      <phone>+33(0)2 98 34 73 66</phone>
      <email>Fabrice.rannou@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Fabrice Rannou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH d'Escartons</name>
      <address>
        <city>Briancon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Girard</last_name>
      <email>fgirard@ch-briancon.fr</email>
    </contact>
    <investigator>
      <last_name>Girard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Cannes</name>
      <address>
        <city>Cannes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe PERRIN</last_name>
      <email>c.perrin@ch-cannes.fr</email>
    </contact>
    <investigator>
      <last_name>Christophe PERRIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHI de Créteil</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gilles Mangiapan, PH</last_name>
      <phone>+33(01) 57 02 20 80</phone>
      <email>Gilles.mangiapan@chicreteil.fr</email>
    </contact>
    <contact_backup>
      <last_name>Zakaria Saakashvili, PH</last_name>
      <email>Zakaria.saakashvili@chicreteil.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Gilles Mangiapan</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zakaria Saakashvili</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU le Bocage</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudio Rabec</last_name>
      <email>claudio.rabec@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Claudio Rabec</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry PEREZ</last_name>
      <email>Thierry.PEREZ@CHRU-LILLE.FR</email>
    </contact>
    <investigator>
      <last_name>Thierry PEREZ</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Florent Favard</last_name>
      <email>Florent.favard@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Florent Favard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cabinet Dr Pereira-Cortese</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pereira-Cortese</last_name>
      <email>dr.pereira.c@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pereira-Cortese</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabrina SACCONI</last_name>
      <email>sacconi.s@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Sabrina SACCONI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GH Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Capucine Morélot-Panzini</last_name>
      <email>capucine.morelot@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Capucine Morélot-Panzini</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Raymond Poincaré</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hélène PRIGENT</last_name>
      <email>helene.prigent@rpc.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Hélène PRIGENT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdellatif Tazi</last_name>
      <email>abdellatif.tazi@sls.aphp.Fr</email>
    </contact>
    <investigator>
      <last_name>Abdellatif Tazi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Wislez</last_name>
      <email>marie.wislez@tnn.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Marie Wislez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Polyclinique les Bleuets</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Nardi</last_name>
      <email>julie.nardi@laposte.net</email>
    </contact>
    <investigator>
      <last_name>Julie Nardi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoine Cuvelier</last_name>
      <email>antoine.cuvelier@chu-rouen.fr</email>
    </contact>
    <investigator>
      <last_name>Antoine Cuvelier</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de St Etienne</name>
      <address>
        <city>Saint-Étienne</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Court-Fortune, PH</last_name>
      <phone>+33(0)4 77 82 82 89</phone>
      <email>Isabelle.court_fortune@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle Court-Fortune</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sedkaoui</last_name>
      <email>sedkaoui.k@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Sedkaoui</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent Plantier, PH</last_name>
      <phone>+33(0)2 47 47 98 44</phone>
      <email>laurent.plantier@univ-tours.fr</email>
    </contact>
    <contact_backup>
      <last_name>Julien Praline, PH</last_name>
      <phone>+33(0)2 47 47 38 25</phone>
      <email>j.praline@chu-tours.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Laurent Plantier</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien Praline</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Joseph</name>
      <address>
        <city>Trélazé</city>
        <zip>49800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrike Lerolle</last_name>
      <phone>+33(0)2 41 89 92 79</phone>
      <email>Lerolle.pneumo@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ulrike Lerolle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2016</study_first_submitted>
  <study_first_submitted_qc>April 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2016</study_first_posted>
  <last_update_submitted>March 16, 2018</last_update_submitted>
  <last_update_submitted_qc>March 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Glycogen Storage Disease Type II</mesh_term>
    <mesh_term>Muscle Weakness</mesh_term>
    <mesh_term>Paresis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

